Juan Cundom

2.1k total citations · 1 hit paper
6 papers, 181 citations indexed

About

Juan Cundom is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Juan Cundom has authored 6 papers receiving a total of 181 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Surgery and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Juan Cundom's work include Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Cancer Diagnosis and Treatment (2 papers). Juan Cundom is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Cancer Diagnosis and Treatment (2 papers). Juan Cundom collaborates with scholars based in Argentina, United Kingdom and United States. Juan Cundom's co-authors include Do‐Youn Oh, Suebpong Tanasanvimon, Antonio Avallone, Juan W. Valle, Mohamed Bouattour, Howard A. Burris, Shukui Qin, Thatthan Suksombooncharoen, Arndt Vogel and Masayuki Kitano and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Hepatology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Juan Cundom

3 papers receiving 179 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

2022 159 citations Do‐Youn Oh, Aiwu Ruth He et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Juan Cundom Argentina	3	150	148	63	36	17	6	181
Thatthan Suksombooncharoen Thailand	3	154 1.0×	135 0.9×	62 1.0×	30 0.8×	16 0.9×	5	171
Claire Hobbs United Kingdom	3	147 1.0×	99 0.7×	74 1.2×	29 0.8×	10 0.6×	8	169
Do-Youn Oh South Korea	5	106 0.7×	159 1.1×	46 0.7×	15 0.4×	18 1.1×	12	189
Y.S. Park South Korea	4	81 0.5×	113 0.8×	70 1.1×	30 0.8×	14 0.8×	12	147
Stefan Angermeier Germany	6	98 0.7×	94 0.6×	138 2.2×	24 0.7×	14 0.8×	28	182
Giovanna Sabella Italy	6	59 0.4×	86 0.6×	62 1.0×	28 0.8×	14 0.8×	23	139
Chimela Ohaji United States	4	65 0.4×	80 0.5×	41 0.7×	32 0.9×	23 1.4×	8	163
Jo Dent United Kingdom	5	49 0.3×	149 1.0×	76 1.2×	20 0.6×	15 0.9×	9	177
Jane V. Thomas United States	5	48 0.3×	87 0.6×	34 0.5×	51 1.4×	15 0.9×	15	123
Coralie Cantarel France	6	66 0.4×	187 1.3×	61 1.0×	65 1.8×	17 1.0×	17	220

Countries citing papers authored by Juan Cundom

Since Specialization

Citations

This map shows the geographic impact of Juan Cundom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juan Cundom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juan Cundom more than expected).

Fields of papers citing papers by Juan Cundom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juan Cundom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juan Cundom. The network helps show where Juan Cundom may publish in the future.

Co-authorship network of co-authors of Juan Cundom

This figure shows the co-authorship network connecting the top 25 collaborators of Juan Cundom. A scholar is included among the top collaborators of Juan Cundom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juan Cundom. Juan Cundom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Oh, Do‐Youn, Aiwu Ruth He, Shukui Qin, et al.. (2025). Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study. Journal of Hepatology. 83(5). 1092–1101. 5 indexed citations

2.

Antonuzzo, Lorenzo, Hidenori Takahashi, Joon Oh Park, et al.. (2025). Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. The Oncologist. 30(7).

3.

Dzienis, Marcin, Juan Cundom, Anna Spreafico, et al.. (2024). Final Analysis of the Phase 4 KEYNOTE-B10 Study: First-Line (1L) Pembrolizumab (pembro) + Carboplatin (carbo) + Paclitaxel (pacli) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC). International Journal of Radiation Oncology*Biology*Physics. 118(5). e3–e4. 1 indexed citations

4.

Cundom, Juan, et al.. (2024). [Cutaneous metastasis of lung cancer].. PubMed. 84(5). 1034–1034.

5.

Kawazoe, Akihito, Rui‐Hua Xu, Maria Passhak, et al.. (2023). LBA-5 Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study. Annals of Oncology. 34. S179–S179. 16 indexed citations

6.

Oh, Do‐Youn, Aiwu Ruth He, Shukui Qin, et al.. (2022). A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.. Journal of Clinical Oncology. 40(4_suppl). 378–378. 159 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact